NFKB1 and breast carcinoma: Consistently with this idea, previous studies have shown that the IL-17RB/IL-17B signaling pathway promotes tumorigenicity and etoposide resistance in breast cancer cells through NFκB activation and Bcl-2 up-regulation [16].